Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Diverticulitis by Phase

  • There are currently 10 ongoing clinical trials involving Diverticulitis

  • Of the 10 trials,4 trials are in Phase II

  • Furthermore, 4 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Diverticulitis by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Diverticulitis, a Gastrointestinal condition. The largest number of ongoing clinical trials for Diverticulitisis conducted in North America. Europe is the other prominent region engaged in Diverticulitis-related drug trials.

Diverticulitis related clinical trial sponsor

Mayo Clinic, Jewish General Hospital, Uppsala University, Emmaus Life Sciences Inc, and Centre Hospitalier Universitaire de Dijon are a few notable clinical trials sponsors involved in Diverticulitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Diverticulitis

Ceftazidime (Fortaz, Fortam, Fortumset, Modacin, Glazidim, ceptaz), Cefepime and tazobactam (Duopime), and Atropine sulphate are among the key marketed drugs involving Diverticulitis.

Ceftazidime (Fortaz, Fortam, Fortumset, Modacin, Glazidim, ceptaz) is an anti-bacterial agent. It functions via Penicillin Binding Protein (PBP) Inhibitor mechanism of action. Ceftazidime is formulated as powder for solution for intramuscular or intravenous route of administration. It is used for the treatment of various bacterial infections caused by different bacterial species. Ceftazidime was first approved in 1983 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including GlaxoSmithKline LLC.

Cefepime and tazobactam (Duopime) is a fixed dose combination, acts as antibacterial agent. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. Cefepime and tazobactam are formulated as injectable powder for solution, for intravenous route of administration. Duopime is indicated for the treatment of uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections and complicated intra-abdominal infections. Cefepime and tazobactam is marketed solely in India by Orchid Pharma Ltd.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward